Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening could catch hidden lung damage after blood clots

NCT ID NCT06865326

Diagnosis Sponsor: Institute of Health Information and Statistics of the Czech Republic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a standard screening method to find a condition called chronic thromboembolic pulmonary hypertension (CTEPH) in people who had a blood clot in their lungs 3 to 12 months earlier. Researchers will check if certain tests, like heart ultrasound or lung scans, can catch CTEPH early. The goal is to see if this approach helps more patients get the right care sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this screening approach could help doctors catch a serious lung condition earlier, leading to faster treatment and better outcomes for patients.
What could go wrong
This is an observational pilot study, so it won't directly test a new treatment. The screening may not prove accurate or cost-effective in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pacients matching all inclusion \& exclusion criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 18 years * Signed consent to participate in the project and GDPR * Patients with an episode of acute pulmonary embolism in the last 3-12 months, with ongoing anticoagulation therapy: 1. Patients with new-onset and ongoing or progressive dyspnea (min. NYHA II) after a pulmonary embolism episode or worsening of dyspnea after a pulmonary embolism episode compared to the status before the episode (at least 1 HYHA grade) or 2. Asymptomatic patients after a pulmonary embolism episode and at least one of the following risk factors: * ECHO evidence of severe PH at diagnosis of PE (PASP \>60 mmHg) * Antiphospholipid syndrome with triple positivity (presence of lupus anticoagulans + anti-beta-2-glycoprotein I (B2GPI) antibodies + anticardiolipin) * Infected permanent venous inlets and cardiac pacing/defibrillation intravascular systems * Presence of ventriculoatrial shunt for treatment of hydrocephalus * Nonspecific intestinal inflammation (ulcerative colitis, Crohn's disease) * History of splenectomy * Myeloproliferative disorders * Chronic osteomyelitis Exclusion Criteria: * Not agreeing to participate in the project * Contraindications to treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pulmonary embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic thromboembolic pulmonary hypertension pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pulmonary thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brno University Hospital

    RECRUITING

    Brno, Czechia

  • Havlíčkův Brod Hospital

    RECRUITING

    Havlíčkův Brod, Czechia

  • Jihlava Hospital

    RECRUITING

    Jihlava, Czechia

  • Náchod Hospital

    RECRUITING

    Náchod, Czechia

  • Pardubice Hospital

    RECRUITING

    Pardubice, Czechia

  • Rychnov nad Kněžnou Hospital

    RECRUITING

    Rychnov nad Kněžnou, Czechia

  • Tábor Hospital

    RECRUITING

    Tábor, Czechia

  • University Hospital Hradec Králové

    RECRUITING

    Hradec Králové, Czechia

  • University Hospital Olomouc

    RECRUITING

    Olomouc, Czechia

  • University Hospital Ostrava

    RECRUITING

    Ostrava, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.